Clofazimine
SIGMA/C8895
Synonym: N,5-
CAS Number: 2030-63-9
Empirical Formula (Hill Notation): C27H22Cl2N4
Molecular Weight: 473.40
EC Number: 217-980-2
MDL Number: MFCD00056793
Linear Formula: C27H22Cl2N4
Product Type: Chemical
| antibiotic activity spectrum | mycobacteria |
| form | powder |
| InChI | 1S/C27H22Cl2N4/c1-17(2)30 |
| InChI key | WDQPAMHFFCXSNU-BGABXYSRSA |
| mode of action | protein synthesis | interferes |
| originator | Novartis |
| Quality Level | 200 ![]() |
| SMILES string | CC(C)N=C1/C=C2N(c3ccc(Cl |
| Application: | Clofazimine has been used: • for antimicrobial preparation • to study its accumulation on macrophages to form crystal-like drug inclusions (CLDIs) • to model drug-induced hepatic granulomatous inflammation • to study the in vivo cargo storage capacity of macrophages |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| General description: | Clofazimine is a riminophenazine, which is used as an antileprosy drug. It is used to treat multidrug-resistant tuberculosis. Clofazimine prevents neutrophil motility and lymphocyte transformation. It has anti-inflammatory effect, which is used to treat discoid lupus erythematosus. Clofazimine has immunosuppressive property. |
| Packaging: | 1, 5 g in glass bottle |
| Preparation Note: | This product is stored at room temperature. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| UNSPSC | 12352200 |

